1
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
13144
Neoplasms
10492
Carcinoma, Non-Small-Cell Lung
6878
Prostatic Neoplasms
6276
Colorectal Neoplasms
5950
Lung Neoplasms
5110
Multiple Myeloma
3579
Pancreatic Neoplasms
3564
Leukemia, Myeloid, Acute
3512
Neoplasm Metastasis
3511
Carcinoma, Hepatocellular
3277
Ovarian Neoplasms
3173
Melanoma
3142
Stomach Neoplasms
3058
Lymphoma
2984
Head and Neck Neoplasms
2608
Recurrence
2557
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2500
Leukemia
2362
Colonic Neoplasms
2328
Brain Neoplasms
2317
Lymphoma, Non-Hodgkin
2269
Uterine Cervical Neoplasms
2193
Rectal Neoplasms
2192
Glioblastoma
2018
Leukemia, Lymphocytic, Chronic, B-Cell
1992
Carcinoma, Renal Cell
1915
Squamous Cell Carcinoma of Head and Neck
1880
Lymphoma, Follicular
1851
Esophageal Neoplasms
1801
Interventions
Saline Solution
1
Infliximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Depressive Disorder, Treatment-Resistant
×
Clear all
NCT00463580
2025-07-08
Infliximab
Emory University
Phase 4
Completed
60 enrolled
15 charts